Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
about
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells.Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.
P2860
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Overcoming sorafenib evasion i ...... to co-deliver MEK-inhibitors.
@en
Overcoming sorafenib evasion i ...... to co-deliver MEK-inhibitors.
@nl
type
label
Overcoming sorafenib evasion i ...... to co-deliver MEK-inhibitors.
@en
Overcoming sorafenib evasion i ...... to co-deliver MEK-inhibitors.
@nl
prefLabel
Overcoming sorafenib evasion i ...... to co-deliver MEK-inhibitors.
@en
Overcoming sorafenib evasion i ...... to co-deliver MEK-inhibitors.
@nl
P2093
P2860
P356
P1433
P1476
Overcoming sorafenib evasion i ...... to co-deliver MEK-inhibitors.
@en
P2093
Andrew X Zhu
Annique M Duyverman
Chih-Chun Chang
Chiung-Fang Chang
Chun-Hung Liu
Cyril H Benes
Dan G Duda
Dong-Yu Gao
Fu-Fei Hsu
Irinel Popescu
P2860
P2888
P356
10.1038/SREP44123
P407
P577
2017-03-09T00:00:00Z
P6179
1084132023